1/41
Looks like no tags are added yet.
How do innate and adaptive immunity differ?
Innate immunity rapidly recognizes common microbial features and tissue damage through cells such as neutrophils, macrophages, dendritic cells, and NK cells, as well as complement. Adaptive immunity uses antigen-specific B and T cells, develops over several days initially, and generates memory.
What is immunotoxicity, and why does it matter for biomaterials?
Adverse effects on immune function or damage from altered immune responses. Biomaterials may cause harmful activation, suppression, hypersensitivity, or autoimmunity, although some intentionally enhance immunity for vaccine delivery.
What are the four characteristics of adaptive immunity?
Specificity, diversity, self-tolerance, and immunologic memory. These allow recognition of particular targets, a broad receptor repertoire, restraint of self-reactivity, and faster responses after re-exposure.
How do antigens and epitopes differ, and how do B and T cells recognize them?
An antigen is specifically recognized by an antibody or lymphocyte receptor; an epitope is the particular molecular feature recognized. B-cell receptors and antibodies bind intact antigens, while conventional T-cell receptors recognize peptide-MHC complexes.
How do humoral and cellular immunity differ?
Humoral immunity uses antibodies secreted by plasma cells derived from B cells. Cellular immunity uses T cells: helper T cells coordinate responses and cytotoxic T cells kill target cells. Helper T cells also support many humoral responses.
What is a hapten, and what does a protein carrier provide?
A hapten is a small molecule that generally cannot induce an adaptive response alone. Association with a protein carrier can make the combination immunogenic and provide peptides for T-cell help. Resulting antibodies may later bind the hapten alone.
How do haptens and adjuvants differ?
A hapten contributes a target for specific recognition, often after association with a carrier protein. An adjuvant enhances the response to an antigen through immune activation and/or improved delivery. Released metal species can act as haptens; vaccine formulations can contain adjuvants.
How can a PRR-activating adjuvant enhance vaccination?
It activates pattern recognition receptors on dendritic cells, increasing co-stimulation and cytokine production so T cells can respond to presented antigen.
How are the layer-by-layer nanoparticle vaccines in the slides assembled and used?
Alternating positively charged SIINFEKL-R9 peptide antigen and negatively charged poly(I:C) adjuvant layers are deposited on gold particles with rinsing between layers. Poly(I:C) mimics double-stranded RNA and activates endosomal TLR3. Co-delivery supports antigen presentation and antigen-specific CD8 T-cell responses.
Where do B and T cells originate and mature, and what does naïve mean?
Both arise from bone marrow precursors. B cells develop primarily in bone marrow, while T cells mature in the thymus. A naïve lymphocyte is mature but has not yet been activated by its specific antigen.
How are lymphocyte diversity and self-tolerance established?
Receptor gene rearrangement generates diverse specificities. Many strongly self-reactive cells are eliminated during development, and additional mechanisms inactivate or restrain self-reactive cells that remain.
What are the steps and outcomes of lymphocyte activation and clonal expansion?
A mature naïve cell recognizes antigen and receives necessary activating signals, then divides into cells with the same specificity. Effector cells perform the current response, and memory cells persist for later exposures.
How do MHC I and MHC II differ?
MHC I typically presents intracellular peptides to CD8 cytotoxic T cells and is expressed by almost all nucleated cells. MHC II typically presents peptides from internalized extracellular proteins to CD4 helper T cells and is expressed by professional antigen-presenting cells.
Which cells are professional antigen-presenting cells, and how do B cells participate?
Dendritic cells, macrophages, and B cells are professional APCs and also express MHC I. B cells bind intact antigen and can present its peptides on MHC II to obtain helper T-cell signals. Dendritic cells are especially important for priming naïve T cells.
How are proteins processed for presentation on MHC I and MHC II?
In the typical MHC I pathway, intracellular proteins are degraded and peptides load onto MHC I in the endoplasmic reticulum. In the MHC II pathway, internalized proteins are degraded and peptides load onto MHC II in vesicles. Complexes then move to the cell surface.
What signals activate and regulate helper T cells?
The T-cell receptor recognizes peptide-MHC II, APC B7 binds T-cell CD28 for co-stimulation, and cytokines guide proliferation and differentiation. CTLA-4 supplies an inhibitory signal that helps limit activation.
What are the main functions of TH1, TH2, TH17, and regulatory T cells?
TH1 supports macrophage activation and responses to intracellular pathogens. TH2 supports IgE-associated and eosinophil responses, including allergy. TH17 promotes inflammation and innate cell recruitment. Regulatory T cells suppress activation and maintain tolerance.
How do cytotoxic T cells and NK cells differ?
Cytotoxic T cells are adaptive cells that recognize specific peptide-MHC I complexes and require priming and clonal expansion when naïve. NK cells are innate cells that respond to activating and inhibitory signals, including stress and reduced MHC I. Both can induce target-cell apoptosis.
What is the basic structure of an antibody, and what do Fab and Fc do?
A typical monomer has two heavy and two light chains joined by disulfide bonds, with two identical antigen-binding sites. Fab contains variable regions that bind antigen; Fc interacts with particular immune-cell receptors and complement proteins.
What are the main actions of antibodies?
Agglutination crosslinks cells or particles into clumps; precipitation forms insoluble complexes with soluble antigens; neutralization blocks attachment or toxin activity; opsonization promotes phagocytosis. Antibodies can also recruit complement or activate cells through Fc receptors.
What determines antibody class, and how do the classes differ in structure?
The heavy-chain constant region determines class. IgG, IgD, and IgE are monomers with two antigen-binding sites. Secretory IgA is commonly a dimer and secreted IgM a pentamer. Multimeric organization increases antigen-crosslinking capacity.
What are the typical locations and functions of IgG and IgM?
IgG is found in blood and extracellular fluid, crosses the placenta, and supports neutralization and opsonization; some subclasses activate complement. IgM is prominent early in primary responses, is usually secreted as a pentamer, and supports agglutination and complement activation.
What are the typical locations and functions of IgA, IgE, and IgD?
IgA protects epithelial surfaces through mucosal secretions, including milk, especially by neutralization. IgE binds mast cells and basophils and participates in immediate hypersensitivity and parasite defense. IgD is an antigen receptor on naïve mature B cells, often alongside IgM.
What do plasma cells, helper T cells, cytotoxic T cells, and memory cells do?
Plasma cells secrete antibodies. Helper T cells support B cells, cytotoxic T cells, and innate cells through signals and cytokines. Cytotoxic T cells kill cells displaying their target peptide-MHC I. Memory B and T cells support faster responses upon re-exposure.
What is complement, and what are its major effects?
Complement is an innate protein cascade that also interacts with antibodies. C3b coats targets for opsonization, C3a and C5a promote inflammation, and C5b-9 forms the membrane attack complex (MAC). Enzymatic amplification allows one convertase to activate many molecules.
How does the classical complement pathway work?
Antigen-bound IgM or suitable IgG recruits C1. Cleavage of C4 and C2 forms C4b2a, a C3 convertase. C3 cleavage produces C3a and C3b; addition of C3b forms a C5 convertase. C5 cleavage releases C5a, while C5b initiates MAC assembly with C6-C9.
How does the alternative complement pathway work, and does it require antibodies?
It does not require antibodies. C3b deposits on a surface, binds factor B, and factor D cleaves B to form C3bBb, a C3 convertase. Amplification deposits more C3b; additional C3b forms a C5 convertase, leading to the shared terminal pathway and MAC.
How is complement regulated, and why is this relevant to biomaterials?
Short-lived reactive intermediates and regulatory proteins limit activation by blocking assembly, dissociating convertases, inactivating components, or preventing MAC formation. Biomaterials lack the full set of host-cell membrane regulators. They cannot be lysed like cells, but complement activation can recruit inflammatory cells and injure surrounding tissue.
What distinguishes the four types of hypersensitivity?
Type I involves IgE-associated mast-cell activation; type II involves antibodies against cell- or tissue-associated targets; type III involves deposited soluble antigen-antibody complexes; type IV involves antigen-specific T cells. Examples are latex allergy, incompatible transfusion, immune-complex injury, and delayed metal contact hypersensitivity, respectively.
How does type I hypersensitivity develop and occur upon re-exposure?
Sensitization produces allergen-specific IgE that binds high-affinity Fc receptors on mast cells and basophils. Re-exposure crosslinks bound IgE, causing release of histamine and other mediators with rapid local or systemic effects. Latex proteins are a biomaterial-associated example.
How do type II and type III hypersensitivity cause tissue injury?
In type II, IgG or IgM binds cell- or tissue-associated targets, allowing complement or Fc-receptor-bearing cells to cause injury. In type III, soluble antigen-antibody complexes deposit in tissue, activate complement, and recruit inflammatory cells that cause damage.
How does type IV hypersensitivity develop, and which metals are relevant?
APCs activate antigen-specific T cells during sensitization. On re-exposure, memory T cells respond and release cytokines, recruiting cells that cause inflammation and injury. The response commonly appears after 24-72 hours. Nickel, cobalt, and chromium can contribute.
How does poison ivy illustrate hapten-associated type IV hypersensitivity?
Urushiol modifies host proteins, which APCs process into peptides. In the illustrated pathway, modified peptides are presented on MHC II to CD4 T cells, producing effector and memory cells. Re-exposure can cause a delayed inflammatory rash; other pathways also contribute.
What mechanisms can produce adaptive responses to biomaterials?
Released chemicals can associate with host proteins as haptens; adsorbed proteins can expose antibody-recognized epitopes; antibodies such as anti-PEG can recognize polymer components; persistent inflammation can favor self-reactivity; and recipient T cells can recognize donor-cell peptide-MHC complexes in scaffolds. Implants do not inevitably cause autoimmunity.
How should immune-response testing of a biomaterial be designed?
Define the concern, such as stimulation, suppression, hypersensitivity, or complement activation. Test relevant material, extracts, or degradation products under appropriate exposure conditions. Include untreated or vehicle controls, a positive control, and separate viability measurements, then combine functional readouts with cell identity and tissue responses.
What do lymphocyte proliferation assays measure, and what are their limitations?
They measure cell division or indirectly assess viable cell activity, comparing stimulated and unstimulated cells with and without the material. An increased signal does not prove antigen-specific allergy; a decreased signal may reflect suppression or cell death. Monocyte co-culture or transwell culture can change the signal.
How do NK functional assays assess immune effects, and what controls are needed?
NK cells are co-cultured with susceptible targets and target-cell killing is compared with and without material or extract. Reduced killing may indicate impaired function, but NK viability and direct effects on target cells must be checked. The slide's TGF-beta example illustrates the method rather than testing a biomaterial.
Which methods assess cytokines, cell identity, cell behavior, and toxicity?
ELISA or multiplex assays measure cytokines; flow cytometry assesses cell populations and activation markers; migration and adhesion assays assess cell behavior; viability or apoptosis assays assess toxicity. Interpret combined results rather than relying on one marker.
What can local tissue studies show, and what can they not establish alone?
Histology shows cells, fibrous tissue, and material. Immunohistochemistry or flow cytometry identifies populations more specifically. Lymphocyte accumulation alone does not establish antigen specificity or a hypersensitivity mechanism; controls, relevant sites, and time points are needed.
How should antibody, complement, and skin-test results be interpreted?
Antigen-specific antibodies show a humoral response but do not prove harm. Complement activation products assess activation more directly than total protein concentration alone. Skin testing can demonstrate sensitization, but a positive result alone does not prove an implant caused symptoms or will fail.
What are the main limitations of in vitro and animal immune-response models?
In vitro assays isolate mechanisms but do not reproduce the full tissue environment. Animal responses can differ from human and individual patient responses. Match model, site, dose, duration, controls, and time points to intended use.
Would no immune response in a SCID mouse establish biomaterial immunocompatibility?
No. Severe combined immunodeficiency limits adaptive immune responses, so the model may fail to reveal mechanisms that an immunocompetent host could develop. An appropriate host response must be assessed using models and assays suited to the intended application.